<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03456830</url>
  </required_header>
  <id_info>
    <org_study_id>ALLN-177-301</org_study_id>
    <nct_id>NCT03456830</nct_id>
  </id_info>
  <brief_title>Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria</brief_title>
  <official_title>Evaluate the Safety and Efficacy of ALLN-177 in Patients With Enteric Hyperoxaluria: A Phase III Randomized, Placebo-Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allena Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allena Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of ALLN-177 in patients
      with enteric hyperoxaluria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 3, multicenter, randomized, double-blind, placebo-controlled study. This
      study is designed to determine whether treatment with ALLN-177 for 28 days can reduce urinary
      oxalate excretion in patients with enteric hyperoxaluria and to evaluate the safety of
      ALLN-177 in this patient population compared to placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 2018</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change from baseline in 24-hour urinary oxalate excretion during Weeks 1-4</measure>
    <time_frame>4 weeks</time_frame>
    <description>Efficacy will be assessed based on percent change from baseline to the mean of Weeks 1-4, derived from all 24-hour collections during Weeks 1-4 on treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a ≥ 20% reduction from Baseline in 24-hour urinary oxalate excretion during Weeks 1-4</measure>
    <time_frame>4 weeks</time_frame>
    <description>Efficacy will be assessed based on proportion of subjects with ≥ 20% reduction from baseline to the mean of Weeks 1-4, derived from all 24-hour collections during Weeks 1-4 on treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Enteric Hyperoxaluria</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ALLN-177</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALLN-177 3750 units per capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 2 capsules with each meal/snack, 3 to 5 times per day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALLN-177</intervention_name>
    <description>ALLN-177 2 capsules with each meal/snack, 3 to 5 times per day</description>
    <arm_group_label>ALLN-177</arm_group_label>
    <other_name>Oxalate decarboxylase</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provided informed consent

          2. Age 18 or older

          3. History of hyperoxaluria secondary to a known underlying enteric disorder associated
             with malabsorption (e.g., bariatric surgery, Crohn's disease, short bowel syndrome, or
             other malabsorption syndrome)

          4. Urinary Oxalate ≥50 mg/24h

        Exclusion Criteria:

          1. Acute renal failure or glomerular filtration rate &lt;30 mL/min/1.73 m2

          2. Unable or unwilling to discontinue Vitamin C supplementation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annamaria Kausz, MD MS</last_name>
    <role>Study Director</role>
    <affiliation>Allena Pharmaceuticals Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Allena Pharmaceuticals, Inc</last_name>
    <phone>617-467-4577</phone>
    <email>clinical301@allenapharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Applied Research Center of Arkansas</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Urology Institute</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Medical Research Group, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pen Bay Medical Center</name>
      <address>
        <city>Rockport</city>
        <state>Maine</state>
        <zip>04856</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2018</study_first_submitted>
  <study_first_submitted_qc>March 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2018</study_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney stones</keyword>
  <keyword>Hyperoxaluria</keyword>
  <keyword>Enteric hyperoxaluria</keyword>
  <keyword>Oxalate</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

